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Cervical screening programmes inmany countries stop at around
the age of 65 andmuch of the focus is often on younger women.
For example, recent media campaigns in England and Wales
have centred on lowering the age at first screening.
Comparatively little attention has been given to older women
despite the fact that they account for about a fifth of cases each
year and half of deaths.1 2 Of the 3121 women diagnosed on
average each year between 2009 and 2011 in the UK, only 64
were younger than 25 compared with 616 who were older than
65.1 As the population ages, this number of older women
affected is set to increase.We argue that screening programmes
should reflect this.
Age distribution of cases
The raw statistics conceal the full impact of cervical cancer on
older women. Although the absolute figures decrease with
increasing age, when the rate of new cases per 100 000 women
is considered, a second peak in diagnoses after the age of 65
becomes apparent (table⇓). The case rate gradually decreases
from 19.7 new diagnoses per 100 000 women aged 30-34 to a
low of 8.6/100 000 women aged 65-69, but then rises again,
reaching 12.5/100 000 in women aged 80-84. Furthermore,
mortality data for the UK from 2010-12 show only seven deaths
a year from cervical cancer in women younger than 25 but 449
deaths in women older than 65—nearly half of the total average
deaths from cervical cancer in any year.2
Although recent research by Castanon and colleagues suggests
that women aged 65 who have had regular screening with
negative results have a relatively low 20 year risk of 8/10 000
women, it also reports that for those women who have not been
screened between the ages of 50 and 64, the 20 year risk rises
to 49/10 000 women.3 This raises several issues.
Screening uptake falls in older women
The proportion of women in England in 2013 who had been
screened in the past five years dropped with age, from 82.4%
of 50-54 year olds to 75.9% of 55-59 year olds and 72.7% of
60-64 year olds.4 These numbers are set to fall further because
uptake is decreasing across all age groups. More than 25% of
older women would therefore not be in the low risk group
defined by Castanon and colleagues.3
The fall in uptake suggests that as women age they perceive
cervical screening to be less important. This is supported by
Waller and colleagues,5who found that only 12% of 55-64 year
old women cited not attending screening as a risk factor for
cervical cancer. In addition, only 2.1% of participants across
their whole sample identified older age as a risk factor,
suggesting that it is perceived as being a younger woman’s
disease. This interpretation is strengthened by the fact that the
age related decline in screening uptake seems to be specific to
cervical screening. The 2010-11 breast cancer screening data
show that 70.7% of invited women aged 45-49 attended breast
screening, increasing to 74.9% in women aged 60-64.6
The perception of cervical cancer as a younger woman’s disease
may have been reinforced by the high profile death in March
2009 of television celebrity Jade Goody at the age of 27.
Although an extra half a million women were screened between
2008 and 2009, the increase was greatest in the under 50s,7with
women aged 26-35 years more likely to be influenced by the
story than those aged 56-64 years.8 The perception of cervical
cancer as a young woman’s problem is likely to have been
further enhanced by high profile media campaigns to reduce
the age of screening after the death of a few young women as
well as the introduction of the human papillomavirus (HPV)
vaccination for teenage girls in 2008. Furthermore, the fact that
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the screening programme ends at 65 implicitly suggests that
older women are no longer at risk.
Older women present with later stages of
cancer
As well as having high rates of cervical cancer, women over 65
are more likely to die from it than younger women.2 Increased
age at the time of diagnosis may contribute to higher mortality,
but lack of awareness that age increases risk may mean women
do not present until their cancer is at an advanced stage. This
could be exacerbated by a lack of knowledge of the symptoms
of cervical cancer, although there has been little research into
awareness in this age group. Low et al explored awareness of
cervical cancer risk factors and symptoms in British women
aged 16-94 divided into four age categories (16-24, 25-39,
40-59, ≥60). Older age predicted increased risk factor and
symptom recognition, but overall awareness was low.9
Even if they know the relevant symptoms, age related changes
may mean older women do not detect them at an early stage. If
sexual activity is reduced through declining libido or loss of a
partner, symptoms such as pain or discomfort during intercourse
or bleeding afterwards may not be identified. Reduced olfactory
sensitivity10 may also delay the identification of unpleasant
smelling vaginal discharge.
Examination of data on age and stage of presentation from 2753
women presenting during 1993-7 shows that only 2% of women
aged ≥70 presented with stage 1A compared with 20% of
women aged 40-54.11 More recent data support a later stage at
diagnosis for older women. In 2009-10, 3.6% of women ≥65
had a diagnosis of stage 1A, 19.9% stage 1B, and 51.1% stage
2 or higher. For women under the age of 65, these figures were
39.2%, 30.5%, and 19.4% respectively.12
Upper age limit for screening
Although the definition of low risk can be debated, 65 is
indisputably an arbitrary cut-off point for screening set in 1988
when life expectancy at birth for a woman in the UKwas nearly
five years lower than today: 78.2 compared with 82.7 in 2013.13
It is true that problems obtaining an adequate and accurate
cervical cytological sample increase with age. These include
difficulties with the examination itself, such as pain caused by
musculoskeletal disorders or vaginal atrophy. Vaginal atrophy
can also lead to increased false positive results, while problems
accessing the transformation zone, which is located higher in
the endocervical canal in older women, can lead to higher false
negative results.14However, these conditions vary fromwoman
to woman, and for many healthy older women, 65 may be too
young for any attendant discomfort or risks to outweigh the
benefit of additional screening. Furthermore, these problems
have mainly been identified for cytology and we are now at a
crossroads in cervical screening whereby HPV testing is likely
to become the primary screening tool and the same problems
may not be relevant.
Age in itself is not a reason for stopping screening. Routine
breast cancer screening in the UK continues until 70 (rising to
73 from 2016 in England) and screening is available on demand
every three years after 70. The upper age limit for routine bowel
screening in England is currently being extended from 69 to 74
(in line with Scotland) and thereafter on demand. Ending
cervical screening at an age at which only half of the women
who will die from the disease have done so seems inappropriate.
Furthermore, using the justification of a low risk, which pertains
only to womenwho have been regularly screened, disadvantages
the 25% or more of women who have not been; these women
are likely to be non-white and to come from lower educational
backgrounds.15
Case for screening older women and
some possible solutions
Elit’s literature review exploring cervical screening in older
women reported that screening is beneficial until at least age
69 in terms of preventing occurrence of and death from cervical
cancer.14 With the exception of the Castanon et al study,3 the
other studies reviewed found that the protective effect of
screening in older women was up to around five years. While
acknowledging the difficulties and costs of screening older
women, she suggests that “the stopping age of screening perhaps
should depend in part on the woman’s characteristics and
preferences.”
Since female life expectancy has increased by almost five years
since the screening programme began in the UK, we should
consider raising the end age to 70 years. In addition, or
alternatively, cervical screening could be provided on demand
every five years for women over 65 (or 70), as is the case for
breast and bowel screening, possibly with an HPV test on exit
from the screening programme. Previous research in the UK16
has explored how older adults (60-74 years) feel about
continuing breast and bowel screening; 78% of respondents did
not agree with age based stoppage policies. However, although
83%wanted a strong recommendation to opt in after the cut-off
point, only 27% said they would be “very likely” to request
screening, with another 33% saying they would be “quite likely”
to do so. This suggests that there would be public support for
increasing the availability of screening, while providing some
reassurance to budget holders that not all eligible women would
take the opportunity.
Increasing the age limit does not address the fact that eligible
women need to attend screening to benefit. Since there is already
a decline in uptake of cervical screening in women over the age
of 55, efforts must be made to increase cervical screening uptake
in this group. If older women believe that they are not at risk
or are at reduced risk of cervical cancer because of their age
and there is no ongoing health literacy aimed at those women,
there is no reason for them to attend routine screening, look out
for symptoms, or re-enter the screening programme if they have
previously opted out. Awareness could be increased for
relatively little cost by giving older women information leaflets
when they attend primary care for other interventions such as
a flu jab or when they have breast cancer screening.
An alternative approach is to send older women a self sampling
kit for HPV. Most studies of self sampling in women do not
include women beyond the age of 65. However, a study in
Canada comparing self sampling with physician cervical
sampling for HPV found 47.9% of older women (age 50-80)
preferred self sampling or had no preference.17 A recent study
found that an in-home return mail kit sent to women aged 30-65
who had not previously responded to a call to screening was
significantly more effective than a recall letter in eliciting a
response.18 Uptake of follow-up cervical screening among the
women with a positive HPV result was 91%. This suggests that
posting kits to older women could reduce the risk for those who
have not taken full advantage of the call-recall system or at least
enable any cancer to be diagnosed at an earlier stage with the
potential to increase healthy years of life expectancy. With the
numbers of older women developing cervical cancer likely to
rise as longevity increases, urgent action is needed.
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Summary points
Women over 65 account for a fifth of new cases of cervical cancer and half of deaths in the UK
Attendance for routine screening falls with age
Health campaigns are needed to increase awareness of risk among older women
The upper age limit of the cervical screening programme needs revisiting
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Table
Table 1| New cases (2009-11) of cervical cancer and deaths (2010-12) in UK by age
DeathsNew casesAge
No/100 000*NoNo/100 000*No
0000<15
000.1215-19
0.372.96220-24
1.32719.141025-29
1.73619.739830-34
2.55219.141135-39
2.96715.736940-44
3.68412.128045-49
3.67410.320950-54
3.76810.418955-59
4.1799.117560-64
5.0808.613165-69
6.5849.912870-74
8.19011.813175-79
9.38212.511080-84
11.911312.4116≥85
*Per 100 000 women in each age group.
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